Topic: pharma CEO

As Glaxo CEO, Andrew Witty was prepping for a future rife with payer pressure that could hit pharma hard. And now, he'll apply that pressure.

After Lilly CEO David Ricks took over in 2016, he revamped management while cutting costs and jobs—and earned nearly $16 million in pay for his efforts.

Former Teva Generics CEO Siggi Olafsson is back in the copycat game—this time, as the new CEO of Jordan’s Hikma Pharmaceuticals.

Perrigo has named Uwe Röhrhoff, former head of German pharma glass and packaging company Gerresheimer, as its new CEO.

Novartis' soon-to-be-ex CEO Joe Jimenez has nailed at least one new job: board member at P&G, courtesy of a proxy fight at the consumer giant.

Yet another Teva executive is heading out the door, and at least one analyst has some concerns about his departure.

It feels as though we say this every year, but it bears repeating: From CEOs and COOs to division chiefs and venture capital partners, women are taking the lead and making an impact all over the life sciences industry.

After seven long months of searching, Teva finally has its new CEO—and as the company hinted it would, it’s poached him from another drugmaker.

Especially after the week Teva’s had, it may need to pay up—big time—to land a CEO that can help it turn its fortunes.